For example, CR-1-31 B treatment (0.25 mg/kg, 2 times per week for 2.5 weeks) results in growth impairment of suDHL-6 xenografts (n = 10, p < 0.05) (Figure 1E) and also in a primary, patient-derived MYC+/BCL2+ diffused large B cell lymphoma (DLBCL) xenograft (0.25 mg/kg, 3 times per week for ~4 weeks) (n = 5, p < 0.05) (Figure 1F,G). The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.